(Q53196556)
Statements
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer (English)
J-C Eymard
F Priou
A Zannetti
D Lepillé
P Kerbrat
P Gomez
B Paule
D Genet
P Hérait
E Ecstein-Fraïssé